MANRESANA de MICOBACTERIOLOGIA, S.L
Manremyc SL is a spin-off from the “Experimental Tuberculosis (TB) Unit,” a research group developing cutting-edge strategies for the prevention & control of human & animal TB. The company is led by Dr. Pere-Joan Cardona (CEO) and focuses on the development of a probiotic that prevents the exacerbation of the immune response responsible for TB pathology & disease. The mission of Manremyc is to impact positively and globally on human health by developing novel TB intervention strategies. In that context, becoming part of the B Corp community represents a key milestone toward the achievement of our business & social goals Becoming a B Corp is the proof of MANREMYC's commitment to its mission. Being able not only to get certified by a third party but also to start a leaning process in how to improve our business practices was our motivation.
Overall B Impact Score
Governance evaluates a company's overall mission, engagement around its social/environmental impact, ethics, and transparency. This section also evaluates the ability of a company to protect their mission and formally consider stakeholders in decision making through their corporate structure (e.g. benefit corporation) or corporate governing documents.
What is this? A company with an Impact Business Model is intentionally designed to create a specific positive outcome for one of its stakeholders - such as workers, community, environment, or customers.
Previous Overall B Impact Scores
Sign up to our Insights newsletter, a monthly digest of the latest news on economic systems change from B Lab Global.